Tong Li

List of Publications by Year
in descending order

39 papers	1,112 citations	471509 17 h-index	414414 32 g-index
41 all docs	41 docs citations	41 times ranked	1419 citing authors

#	Article	IF	Citations
1	Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. Journal of Hepatology, 2016, 65, 700-710.	3.7	331
2	Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naÃ¯ve Chinese patients. Antiviral Research, 2010, 85, 512-519.	4.1	83
3	Effects of amino acid substitutions in hepatitis B virus surface protein on virion secretion, antigenicity, HBsAg and viral DNA. Journal of Hepatology, 2017, 66, 288-296.	3.7	65
4	Serum Hepatitis B Virus DNA, RNA, and HBsAg: Which Correlated Better with Intrahepatic Covalently Closed Circular DNA before and after Nucleos(t)ide Analogue Treatment?. Journal of Clinical Microbiology, 2017, 55, 2972-2982.	3.9	61
5	Natural triterpenoids from licorice potently inhibit SARS-CoV-2 infection. Journal of Advanced Research, 2022, 36, 201-210.	9.5	57
6	Molecular characterization of resistance, virulence and clonality in vancomycin-resistant Enterococcus faecium and Enterococcus faecalis : A hospital-based study in Beijing, China. Infection, Genetics and Evolution, 2015, 33, 253-260.	2.3	52
7	Mutations in preS genes of genotype C hepatitis B virus in patients with chronic hepatitis B and hepatocellular carcinoma. Journal of Gastroenterology, 2007, 42, 761-768.	5.1	50
8	The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro. Signal Transduction and Targeted Therapy, 2020, 5, 275.	17.1	40
9	Hepatitis B Surface Antigen Activates Unfolded Protein Response in Forming Ground Glass Hepatocytes of Chronic Hepatitis B. Viruses, 2019, 11, 386.	3.3	35
10	Correlation of hepatitis B virus (HBV) genotypes and mutations in basal core promoter/precore with clinical features of chronic HBV infection. Liver International, 2007, 27, 240-246.	3.9	26
11	Randomized, threeâ€arm study to optimize lamivudine efficacy in hepatitis <scp>B</scp> e antigenâ€positive chronic hepatitis <scp>B</scp> patients. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 748-755.	2.8	26
12	Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/ nucleotide analogue treatment among Chinese chronic hepatitis B patients. Antiviral Therapy, 2010, 15, 1171-1178.	1.0	25
13	Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China. Human Vaccines and Immunotherapeutics, 2017, 13, 909-915.	3.3	25
14	Discrepancy of potential antiviral resistance mutation profiles within the HBV reverse transcriptase between nucleos(t)ide analogueâ€untreated and â€treated patients with chronic hepatitis B in a hospital in China. Journal of Medical Virology, 2012, 84, 207-216.	5.0	22
15	Higher detection rates of amino acid substitutions in HBV reverse transcriptase/surface protein overlapping sequence is correlated with lower serum HBV DNA and HBsAg levels in HBeAg-positive chronic hepatitis B patients with subgenotype B2. Infection, Genetics and Evolution, 2016, 40, 275-281.	2.3	20
16	Amino acid similarities and divergences in the small surface proteins of genotype C hepatitis B viruses between nucleos(t)ide analogue-naÃ¯ve and lamivudine-treated patients with chronic hepatitis B. Antiviral Research, 2014, 102, 29-34.	4.1	18
17	Hepatitis B virus basal core promoter mutations A1762T/G1764A are associated with genotype C and a low serum HBsAg level in chronically-infected HBeAg-positive Chinese patients. Antiviral Research, 2012, 96, 108-114.	4.1	17
18	Identified human breast milk compositions effectively inhibit SARS-CoV-2 and variants infection and replication. IScience, 2022, 25, 104136.	4.1	17

#	Article	IF	Citations
19	Naturally occurring deletion/insertion mutations within HBV whole genome sequences in HBeAg-positive chronic hepatitis B patients are correlated with baseline serum HBsAg and HBeAg levels and might predict a shorter interval to HBeAg loss and seroconversion during antiviral treatment. Infection, Genetics and Evolution, 2015, 33, 261-268.	2.3	16
20	Nearly half of Ultrio plus NAT non-discriminated reactive blood donors were identified as occult HBV infection in South China. BMC Infectious Diseases, 2019, 19, 574.	2.9	15
21	Naturally occurring deletions/insertions in HBV core promoter tend to decrease in HBeAg-positive chronic hepatitis B patients during antiviral therapy. Antiviral Therapy, 2015, 20, 623-632.	1.0	14
22	Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: in vitro replication phenotype. Hepatology International, 2013, 7, 443-450.	4.2	10
23	A novel cell culture model reveals the viral interference during hepatitis B and C virus coinfection. Antiviral Research, 2021, 189, 105061.	4.1	10
24	Novel HBV recombinants between genotypes B and C in 3â€²-terminal reverse transcriptase (RT) sequences are associated with enhanced viral DNA load, higher RT point mutation rates and place of birth among Chinese patients. Infection, Genetics and Evolution, 2018, 57, 26-35.	2.3	9
25	A Predictive Model Using N-Glycan Biosignatures for Clinical Diagnosis of Early Hepatocellular Carcinoma Related to Hepatitis B Virus. OMICS A Journal of Integrative Biology, 2020, 24, 415-423.	2.0	9
26	The Genotype (A to H) Dependent N-terminal Sequence of HBV Large Surface Protein Affects Viral Replication, Secretion and Infectivity. Frontiers in Microbiology, 2021, 12, 687785.	3.5	9
27	MADS-Box Transcription Factor MadsA Regulates Dimorphic Transition, Conidiation, and Germination of Talaromyces marneffei. Frontiers in Microbiology, 2018, 9, 1781.	3.5	8
28	On-treatment quantitative hepatitis B e antigen predicted response to nucleos(t)ide analogues in chronic hepatitis B. World Journal of Hepatology, 2016, 8, 1511.	2.0	7
29	Impacts of HBV rtH55R polymerase substitution on viral replication and rtM204I/V resistance to nucleoside/nucleotide antiviral drugs. Antiviral Therapy, 2017, 23, 33-42.	1.0	5
30	Comparison of Abbott and Da-an real-time PCR for quantitating serum HBV DNA. World Journal of Gastroenterology, 2014, 20, 11762.	3.3	5
31	Characterization of Serum HBV RNA in Patients with Untreated HBeAg-Positive and -Negative Chronic Hepatitis B Infection. Hepatitis Monthly, 2018, 18, .	0.2	4
32	The Effect of the Hepatitis B Virus Surface Protein Truncated sC69âˆ— Mutation on Viral Infectivity and the Host Innate Immune Response. Frontiers in Microbiology, 2019, 10, 1341.	3.5	3
33	Naturally Occurring Mutations within HBV Surface Promoter II Sequences Affect Transcription Activity, HBsAg and HBV DNA Levels in HBeAg-Positive Chronic Hepatitis B Patients. Viruses, 2019, 11, 78.	3.3	3
34	HBV Drug Resistance Substitutions Existed before the Clinical Approval of Nucleos(t)ide Analogues: A Bioinformatic Analysis by GenBank Data Mining. Viruses, 2017, 9, 199.	3.3	2
35	Characteristics of HBV infection in 705 HIV-infected patients under lamivudine-based antiretroviral treatment from three regions in China. Infection and Drug Resistance, 2018, Volume 11, 1635-1644.	2.7	2
36	The nucleotide changes within HBV core promoter/precore during the first 12weeks of nucleos(t)ide treatment might be associated with a better virological response. Infection, Genetics and Evolution, 2017, 49, 116-121.	2.3	1

#	Article	IF	Citations
37	The modulation of HBsAg level by sI126T is affected by additional amino acid substitutions in the S region of HBV. Infection, Genetics and Evolution, 2019, 75, 104006.	2.3	1
38	The enhancement role of Matrigel on HBV infection in HepG2-NTCP cells. Journal of Virological Methods, 2022, 299, 114345.	2.1	1
39	Hepatitis B Virus Pregenomic RNA Reflecting Viral Replication in Distal Non-tumor Tissues as a Determinant of the Stemness and Recurrence of Hepatocellular Carcinoma. Frontiers in Microbiology, 2022, 13, 830741.	3.5	1